Patents by Inventor Patrick Deroy
Patrick Deroy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230355813Abstract: Systems and methods for heteroaromatic silicon fluoride compounds as radiopharmaceuticals with theranostic properties are described. The theranostic heteroaromatic silicon fluoride compounds can be conjugated with various disease binding ligands and/or chelators for imaging and therapeutic applications.Type: ApplicationFiled: April 20, 2023Publication date: November 9, 2023Applicant: Fuzionaire Diagnostics, Inc.Inventors: Christopher Martin Waldmann, Thomas A. Singleton, Anton A. Toutov, Carl Daniel Estrada, Prashant Suresh Deore, Julie Delecueillerie, Patrick DeRoy, Alexandre Larivée, Alexey Kostikov, Jean-Philip George Lumb, HyunJune Jun, En Zhao, Ryan Christopher Clark, Burhan Ahmed Hussein, Bren Jordan Perez Atienza
-
Patent number: 11040957Abstract: The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.Type: GrantFiled: December 5, 2018Date of Patent: June 22, 2021Assignees: Dana-Farber Cancer Institute, Inc., Syros Pharmaceuticals, Inc.Inventors: Stephane Ciblat, Patrick Deroy, Nathanael Gray, Melissa Leblanc, Jason J. Marineau, Joel Moore, Kevin Sprott, Tinghu Zhang, M. Arshad Siddiqui, Anzhelika Kabro, Serge Leger, Stephanie Roy, Darby Schmidt, Dana K. Winter, Michael Bradley, Tom Miller
-
Publication number: 20190292167Abstract: The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.Type: ApplicationFiled: December 21, 2018Publication date: September 26, 2019Inventors: Stephane Ciblat, Patrick Deroy, Melissa Leblanc, Jason J. Marineau, Joel Moore, Stephanie Roy, M. Arshad Siddiqui, Kevin Sprott, Dana K. Winter, Anzhelika Kabro, Serge Leger, Tom Miller, Darby Schmidt, Michael Bradley
-
Publication number: 20190241541Abstract: The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.Type: ApplicationFiled: December 5, 2018Publication date: August 8, 2019Inventors: Stephane Ciblat, Patrick Deroy, Nathanael Gray, Melissa Leblanc, Jason J. Marineau, Joel Moore, Kevin Sprott, Tinghu Zhang, M. Arshad Siddiqui, Anzhelika Kabro, Serge Leger, Stephanie Roy, Darby Schmidt, Dana K. Winter, Michael Bradley, Tom Miller
-
Patent number: 9708332Abstract: Compounds of Formula (I), wherein R1, R2, R3, R4 and n are defined herein, are useful as inhibitors of RSV.Type: GrantFiled: October 29, 2013Date of Patent: July 18, 2017Assignee: MEDIVIR ABInventors: Claudio Sturino, Teddy Halmos, Anne Decor, Martin Duplessis, Patrick Deroy, Araz Jakalian, Louis Morency, Cyrille Kuhn, Chantal Grand-Maitre, Martin Tremblay, Christian Brochu
-
Publication number: 20160272646Abstract: Compounds of Formula (I), wherein R1, R2, R3, R4 and n are defined herein, are useful as inhibitors of RSV.Type: ApplicationFiled: October 29, 2013Publication date: September 22, 2016Inventors: Claudio STURINO, Teddy HALMOS, Anne DECOR, Martin DUPLESSIS, Patrick DEROY, Araz JAKALIAN, Louis MORENCY, Cyrille KUHN, Chantal GRAND-MAITRE, Martin TREMBLAY, Christian BROCHU
-
Publication number: 20160264551Abstract: The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, in duce cellular apoptosis and/or inhibit transcription in the subject.Type: ApplicationFiled: October 17, 2014Publication date: September 15, 2016Applicants: SYROS PHARMACEUTICALS, INC., DANA-FARBER CANCER INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC.Inventors: Stephane Ciblat, Patrick Deroy, Nathanael Gray, Melissa Leblanc, Jason J. Marineau, Joel Moore, Kevin Sprott, Tinghu Zhang, M. Arshad Siddiqui, Anzhelika Kabro, Serge Leger, Tom Miller, Stephanie Roy, Darby Schmidt, Dana K. Winter, Michael Bradley
-
Publication number: 20160264552Abstract: The present invention provides novel compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.Type: ApplicationFiled: October 17, 2014Publication date: September 15, 2016Inventors: Stephane Ciblat, Patrick Deroy, Melissa Leblanc, Jason J. Marineau, Joel Moore, Stephanie Roy, M. Arshad Siddiqui, Kevin Sprott, Dana K. Winter, Anzhelika Kabro, Serge Leger, Tom Miller, Darby Schmidt, Michael Bradley
-
Patent number: 9399645Abstract: Compounds of formula (I) and pharmaceutical compositions thereof: wherein A1 A2 and A3 are each independently selected from the group consisting of N and CR3, wherein R1 is an optionally substituted heterocyclyl or an optionally substituted —(C1-6)alkyl-heterocyclyl, R2 is an optionally substituted aryl or an optionally subsisted heteroaryl, R4 is an optionally substituted aryl, an optionally substituted heterocyclyl or an optionally substituted heteroaryl, useful as an inhibitor of HIV replication.Type: GrantFiled: December 19, 2012Date of Patent: July 26, 2016Assignee: Boehringer Ingelheim International GmbHInventors: Claudio Sturino, Pierre Beaulieu, Patrick Deroy, Martin Duplessis, Clint James, Jean-Eric Lacoste, Joannie Minville, Louis Morency, Sébastien Morin, Bruno Simoneau, Martin Tremblay
-
Publication number: 20150011531Abstract: Compounds of formula (I) and pharmaceutical compositions thereof: wherein A1 A2 and A3 are each independently selected from the group consisting of N and CR3, wherein R1 is an optionally substituted heterocyclyl or an optionally substituted —(C1-6)alkyl-heterocyclyl, R2 is an optionally substituted aryl or an optionally subsisted heteroaryl, R4 is an optionally substituted aryl, an optionally substituted heterocyclyl or an optionally substituted heteroaryl, useful as an inhibitor of HIV replication.Type: ApplicationFiled: December 19, 2012Publication date: January 8, 2015Applicant: Boehringer Ingelheim International GmbHInventors: Claudio Sturino, Pierre Beaulieu, Patrick Deroy, Martin Duplessis, Clint James, Jean-Eric Lacoste, Joannie Minville, Louis Morency, Sébastien Morin, Bruno Simoneau, Martin Tremblay
-
Publication number: 20130150350Abstract: Compounds of formula (I) wherein m, R1, R2, R3, X and Y are defined herein, are useful as inhibitors of HIV replication.Type: ApplicationFiled: February 9, 2011Publication date: June 13, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Bruno Simoneau, Patrick Deroy, Lee Fader, Anne-Marie Faucher, Alexander Gagnon, Chantal Grand-Maitre, Stephen Kawai, Serge Landry, Jean-Francois Mercier, Jean Rancourt
-
Patent number: 8349839Abstract: Compounds of formula (I): wherein R1, R2, A1, A2, A3, A4, X and Y are as defined herein, are useful as inhibitors of HIV replication.Type: GrantFiled: April 8, 2010Date of Patent: January 8, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Claudio Sturino, Patrick Deroy, Martin Duplessis, Paul J. Edwards, Anne-Marie Faucher, Teddy Halmos, Clint James, Jean-Eric Lacoste, Eric Malenfant, Joannie Minville, Louis Morency, Sebastien Morin, Martin Tremblay, Christiane Yoakim
-
Patent number: 8198458Abstract: Compounds of formula (I): wherein Ar, X, R1, R2, R3 and R4 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against wild type and single or double mutant strains of HIV.Type: GrantFiled: February 3, 2009Date of Patent: June 12, 2012Assignee: Boehringer Ingelheim International GmbHInventors: Patrick DeRoy, Anne-Marie Faucher, Alexandre Gagnon, Serge R. Landry, Sebastien Morin, Jeffrey O'Meara, Bruno Simoneau, Bounkham Thavonekham, Christiane Yoakim
-
Patent number: 8039638Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3 and R4 are as defined herein, compositions and uses thereof for treating human immunodeficiency virus (HIV) infection. In particular, the present invention provides novel inhibitors of HIV replication, pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HIV infection.Type: GrantFiled: December 3, 2007Date of Patent: October 18, 2011Assignee: Boehringer Ingelheim International GmbHInventors: Christiane Yoakim, Patrick Deroy, Martin Duplessis, Alexandre Gagnon, Sylvie Goulet, Oliver Hucke, Christopher Lemke, Simon Suprenant
-
Publication number: 20100261714Abstract: Compounds of formula (I): wherein R1, R2, A1, A2, A3, A4, X and Y are as defined herein, are useful as inhibitors of HIV replication.Type: ApplicationFiled: April 8, 2010Publication date: October 14, 2010Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Claudio STURINO, Patrick DEROY, Martin DUPLESSIS, Paul J. EDWARDS, Anne-Marie FAUCHER, Teddy HALMOS, Clint JAMES, Jean-Eric LACOSTE, Eric MALENFANT, Joannie MINVILLE, Louis MORENCY, Sebastien MORIN, Martin TREMBLAY, Christiane YOAKIM
-
Publication number: 20100069353Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3 and R4 are as defined herein, compositions and uses thereof for treating human immunodeficiency virus (HIV) infection. In particular, the present invention provides novel inhibitors of HIV replication, pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HIV infection.Type: ApplicationFiled: December 3, 2007Publication date: March 18, 2010Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Christiane Yoakim, Patrick Deroy, Martin Duplessis, Alexandre Gagnon, Sylvie Goulet, Oliver Huecke, Christopher Lemke, Simon Surprenant
-
Publication number: 20090143370Abstract: Compounds of formula (I): wherein Ar, X, R1, R2, R3 and R4 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against wild type and single or double mutant strains of HIV.Type: ApplicationFiled: February 3, 2009Publication date: June 4, 2009Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Patrick DeROY, Anne-Marie FAUCHER, Alexandre GAGNON, Serge LANDRY, Sebastien MORIN, Jeffrey O'MEARA, Bruno SIMONEAU, Bounkham THAVONEKHAM, Christiane YOAKIM
-
Patent number: 7517998Abstract: Compounds of formula (I): wherein Ar, X, R1, R2, R3 and R4 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against wild type and single or double mutant strains of HIV.Type: GrantFiled: May 24, 2005Date of Patent: April 14, 2009Assignee: Boehringer Ingelheim International GmbHInventors: Patrick Deroy, Anne-Marie Faucher, Alexandre Gagnon, Serge Landry, Sebastien Morin, Jeffrey O'Meara, Bruno Simoneau, Bounkham Thavonekham, Christiane Yoakim
-
Patent number: 7300948Abstract: Inhibitors of HIV reverse transcriptase which are useful for the treatment of HIV infection. Exemplars of the invention are compounds of the formula wherein the substituents are as defined in the following table R1 R2 R4 R5 R8a F CF3 Me H —OH F CF3 Cl H —OH F CF3 Me H —O—CH2CO2H Cl CN Cl H —OH.Type: GrantFiled: September 29, 2005Date of Patent: November 27, 2007Assignee: Boehringer Ingelheim International GmbHInventors: Pierre Bonneau, Patrick Deroy, Alexandre Gagnon, Jeffrey O′Meara, Bruno Simoneau, Christiane Yoakim
-
Publication number: 20060069261Abstract: Inhibitors of HIV reverse transcriptase which are useful for the treatment of HIV infection. Exemplars of the invention are compounds of the formula wherein the substituents are as defined in the following table.Type: ApplicationFiled: September 29, 2005Publication date: March 30, 2006Applicant: Boehringer Ingelheim International GmbHInventors: Pierre Bonneau, Patrick Deroy, Alexandre Gagnon, Jeffrey O'Meara, Bruno Simoneau, Christiane Yoakim